 |
|
|
| |
Persistently detectable serum HBV DNA and pgRNA is
associated with subsequent hepatocellular carcinoma
development in chronic hepatitis B patients receiving
chronic NRTI treatment
|
| |
| |
AASLD 2020 Nov 11-16
Reported by Jules Levin
Authors: Lung-Yi Mak1,2, Qi Huang3, Danny Ka-Ho Wong1,2, Ka-Shing Cheung1,4, Kwan-Lung Ko1, Ran Yan3, Lea Ouyang3, James Fung1,2, Wai-Kay Seto1,2,4, Man-Fung Yuen1,2
1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong 2 State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong 3 Assembly Biosciences, Inc 4 Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
Disclosure: QH ,RY and LO are employees of Assembly Biosciences. WKS received speaker's fee from AstraZeneca and Mylan, is an advisory board member and received speaker's fees from AbbVie, and is an advisory board member, received speaker's fees and researching funding from Gilead Sciences. J Fung is an advisory board member of Gilead Sciences. MFY received research funding from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Springbank Pharmaceuticals, Sysmex Corporation, and is an advisory board member and/or received research funding from Abbvie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals. LYM, DKHW, KSC and KLK declared no conflict of interest.
|
| |
|
|
|
|
|
